Loading rounds…
Loading rounds…
Explore funding rounds, the companies behind them and the investors taking part.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| M MEDIPOSTCompany profile Develops allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven deg... Develops allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven deg... | $140M | Undisclosed | Biotech | United States | Investors | |
| b bit.bioCompany profile Creates functional, human-relevant cells and models for research, drug discovery, and development Creates functional, human-relevant cells and models for research, drug discovery, and development |
Ranked by rounds participated in · All time
AusperBio, Abcuro, Infinimmune
Epicrispr Biotechnologies, Draig Therapeutics, Triveni Bio
LifeMine Therapeutics, Ollin Biosciences, SonoThera
Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics
Leal Therapeutics, Amplifica Holdings Group, InduPro
Explore published rounds while the next edition is being prepared.
| $50M |
| Series CSeries C+ |
| Biotech |
| United Kingdom |
| Investors |
| AT Develops therapeutics for pulmonary diseases, specifically COPD | $200M | Series A | Biotech | United States | Investors |
| V Builds technologies for spatial biology and multi-omics innovation | $48M | Series A | Biotech | United States | Investors |
| A Develops super-resolution microscopy end-to-end solutions | Undisclosed | Series B | Biotech | France | Investors |
| ET Enodia TherapeuticsCompany profile Develops small-molecule therapies for targeted protein degradation at the point of synthesis Develops small-molecule therapies for targeted protein degradation at the point of synthesis | €20.7M | Seed | Biotech | France | Investors |
| E EpiBiologicsCompany profile Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo... Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo... | $107M | Series B | Biotech | United States | Investors |
| PD Perceptive DiscoveryCompany profile Provides preclinical and translational solutions for oncology and radiopharmaceutical programs Provides preclinical and translational solutions for oncology and radiopharmaceutical programs | $15M | StrategicUndisclosed | Biotech | United Kingdom | Investors |
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners |
| NT Nocion TherapeuticsCompany profile Develops novel small molecule therapies for treatment of serious conditions involving cough, itch... Develops novel small molecule therapies for treatment of serious conditions involving cough, itch... | $23M | Series B+Series B | Biotech | United States | Investors Undisclosed |